Edgar Ben-Josef M.D.
Member of the Board of Directors

Dr. Edgar Ben-Josef is Associate Professor of Radiation Oncology at Wayne State University School of Medicine in Detroit, Michigan, Staff Physician at the Department of Radiation Oncology at the VA Medical Center in Allen Park, Michigan and Attending Physician at Gershenson Radiation Oncology Center at Harper Hospital in Detroit, Michigan.

He also serves on the The Karmanos Cancer Institute Clinical Trials Committee and the National Cancer Institute Quick Trials for Prostate Cancer Therapy Scientific Review Panel. He also served as a consultant to Amgen Inc., (AMGN) relating to the development of a new agent for the treatment of prostate cancer.

He is the recipient of research grants from U.S. Bioscience Inc., SafeScience Inc., Amgen Inc., and Roche Laboratories Inc, and received the award for Best Resident Paper from Wayne State University, 1992 Radiation Oncology Research Day.

He is a member of the American Society for Therapeutic Radiology and Oncology (since 1991), The Michigan Society of Therapeutic Radiologists (since 1995), Genitourinary Committee of the Radiation Therapy Oncology Group (since 1995), Genitourinary Committee of the South West Oncology Group (since 1996), European Society for Therapeutic Radiology and Oncology (since 1995) and the American Society of Clinical Oncology (since 1995). He is a Diplomate of the American Board of Radiology and holds medical licenses from Israel, Michigan, FMGEMS and FLEX. Dr. Ben-Josef was a Reseach Associate at Wayne State School of Medicine, Department of Radiation Oncology, Division of Cancer Biology from 1993 - 1995 and is a 1986 graduate of The Hebrew University - Hadassah School of Medicine in Jerusalem, Israel.


Publications and Presentations

Publications:
Original observations

  1. Ben-Josef E, Aref A. Int. J. Radiation Oncology Biol. Phys., 27:992, (1993). Groin irradiation is a viable option in carcinoma of the vulva. (Letter to the Editor)
  2. Ben-Josef E, Lucas RD, Vasan S, Porter AT. Nuc Med Communications 16:457-463, (1995). Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation.
  3. Ben-Josef E, Maughan RL, Vasan S, Porter AT. Nuc Med Communications 16: 452-456, (1995). A direct measurement of strontium-89 activity in bone metastases.
  4. Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renauld C, Walz DA, Honn KH. Cancer Research 55:698-704, (1995). Solid tumor cells express functional "tethered-ligand" thrombin receptor.
  5. Ben-Josef E, Mesina J, Shaw L, Shamsa F, Porter AT. Radiation Research 143: 107-110, (1995). Topical application of WR-2721 achieves high concentrations in the rectal wall.
  6. Ben-Josef E, Court W. Dis. Colon Rectum 38: 1088-1092, (1995). Whole abdominal radiotherapy and concomitant 5-Fluorouracil as adjuvant therapy in advanced colon cancer.
  7. Ben-Josef E, Maughan RL, Vasan S, Porter AT. Bone Depeche 2(3): 77-79, (1996). A direct measurement of strontium-89 activity in bone metastases.
  8. Ben-Josef E. Int. J. Radiation Oncology Biol. Phys. 32(4): 1267, (1995). Dose-response relationship for radiation therapy of subclinical disease (Letter to the Editor).
  9. Ben-Josef E. Int. J. Radiation Oncology Biol. Phys. 35(1):197, (1996). Re: Algan et al. Localization of the prostatic apex for radiation treatment planning. (Letter to the Editor).
  10. Ben-Josef E., Shamsa F, Forman JD. Cancer 82:1334-1342, (1998). Predicting the outcome of radiotherapy for prostate cancer: A model building strategy.
  11. Ben-Josef E., Shamsa F. Int. J. Radiation Oncology Biol. Phys. 39(3):776-777, (1997). Pd-103 brachytherapy and external-beam radiotherapy in locally advanced prostate cancer. (Letter to the Editor)
  12. Aref A, Ben-Josef E, Shamsa F, Devi S, Fontanesi J, Dragovic J. J of Brachytherapy Int'l 13: 17-22, (1997). Neutron radiotherapy for salivary gland tumors at Harper Hospital.
  13. Maughan LR, Lucas DR, Chuba PJ, Porter AT, Ben-Josef E. Medical Physics 24(8):1241-1244, (1997). The elemental composition of tumors: kerma data for neutrons.
  14. Ben-Josef E et al. Int. J. Rad. Onc. Biol. Phys. 40(4): 915-921, (1998). Radiotherapeutic management of osseous metastases: a survey of current patterns of care.
  15. Ben-Josef E. Radiother Oncol 48:344-345, (1998). Nimorazole as a hypoxic-cell radiosensitizer in supraglottic larynx and pharynx carcinoma.
  16. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG. The Prostate 38:118-125, (1999). Prostate Secretory Protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis.
  17. Ben-Josef E, Chuba P, Fontanesi J, Ryan JR, Zalupski M, Lucas DR, Porter AT. J of Brachytherapy Int'l 15:73-84, (1999). A brachytherapy boost may improve outcome of radiotherapy in soft-tissue sarcoma of the extremities.
  18. Ben-Josef E, et al. J Urol 161(3):970-976, (1999). Hormone-Refractory Prostate Cancer Cells Express Functional FSH Receptor
  19. Ben-Josef E, Shamsa F, Youssef E, Porter AT. Int J Radiat Oncol Biol Phys 45(3):715-719, (1999). External beam radiotherapy for painful osseous metastases; pooled data dose-response analysis.
  20. Maughan RL, Chuba P, Porter AT, Ben-Josef, E. Med Phys 26(3):472-477, (1999). Mass energy-absorption coefficients and mass collision stopping powers for electrons in tumors of various histologies.
  21. Joshi B, Taffe BG, Zhu Z, Wahl S, Tian H, Ben-Josef E, Taylor JD, Porter AT, Tang DG. Cancer Research 59: 4343-4355, (1999). Apoptosis inducation by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain (MRC)1
  22. Ben-Josef E, Porter AT, Han S, Mertens W, Chuba P, Fontana J, Hussain M. Int J Radiat Oncol Biol Phys 49 (3): 699-703, (2001). Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results.
  23. Tobi M, Hatfield J, Adsay V, Galagan K, Kozarek R, Inagaki M, Kasai S, Tokusashi Y, Obara T, Hruban RH, Lough J, Barkun AN, Jabbari M, Sheikh R, Ruebner B, Lawson M, Ben-Josef E, Fliegel S. (submitted to JNCI). The prognostic significance of Adnab-9, an anti-colonic adenoma antibody, in Intraductal Papillary Mucinous Neoplasms of the pancreas.

Review Articles

  1. Porter AT, Ben-Josef E. Current Opinions in Oncology 6: 607-610, (1994). Systemic administration of new therapeutic radioisotopes including phosphorus, strontium, samarium and rhenium.
  2. Porter AT. Ben-Josef E. Cancer (in press). Strontium-89 and other systemic radionucleids for palliation of pain from osseous metastases.
  3. Ben-Josef E, Porter AT. Seminars in Urologic Oncology 1: 20-25, (1995). Radiotherapy of T1c prostate cancer.
  4. Chuba PJ, Porter AT, Ben-Josef E, Hart K, Forman JD. J. Endocrinology 3:1-7, (1996). The curative treatment of prostate cancer with combination of radiation and hormone therapies.
  5. Chuba PJ, Forman JD, Ben-Josef E, Hart K, Porter AT. Anticancer Research 17:1449-1454, (1997). Clinical Startegies for improving the radiotherapeutic management of prostate cancer.
  6. Ben-Josef E, Porter AT. Annals of Medicine 29: 31-35, (1997). Radioisotopes in the treatment of bone metastases.
  7. Porter AT, Ben-Josef E. Urology International (in press). The management of locally advanced prostate cancer: a case management.
  8. Ben-Josef E, Porter AT. Bone Depeche 3(3):77-80, (1997). Radioisotopes in the treatment of bone metastases.
  9. Ben-Josef E. Mediguide to Urology 10(6):1-6, (1997). Advances in external-beam radiotherapy for prostate cancer.
  10. Carson, CC, Ben-Josef E, Freeman JA, Graham S. Medical Publications, (1997). Prostate Cancer: Diagnostic and Treatment Challenges, a discussion with five case histories.
  11. Samarium-153 lexidronam for painful bone metastses. The Medical Letter on Drugs and Therapeutics 39: 1008, (1997).
  12. Ben-Josef E, Davis LP, Porter AT. CA-A Cancer Journal for Clinicians 48(6): 361-374, (1998). Systemic Bone-Seeking radionuclides for Palliation of painful Osseous Metastases: Current Concepts. Mertens WC, Filipczack LA,
  13. Ben-Josef E, Garde SV. Institute for Medical Studies, April (2000). Humoral Mechanisms in Prostate Cancer - A Role for FSH. Porter AT.
  14. Porter AT, Ben-Josef E. Urologic Oncology (in press). Humoral Mechanisms in Prostate Cancer: A Role for FSH.

Books and Chapters

  1. Porter AT, Videtic Gregory, Ben-Josef E. Strontium-89 in the treatment of bony metastases. In: Important Advances in Oncology. Ed: DeVita VT, Hellman S and Rosenberg SA. J.B. Lippincott, Philadelphia (1995.)
  2. Porter AT, Videtic Gregory, Ben-Josef E. External-beam radiotherapy for prostate cancer: In: Atlas of Clinical Urology. Series Eds: Vaigjam ED Jr., Perlmutter AP. Eds: McConnell JD, Scardino PT. Current Medicine, Inc., Philadelphia, Pennsylvania, 1999.
  3. Porter AT, Benda R, Ben-Josef E. The management of painful osseous metastases. In: Clinical Radiation Oncology. Ed: Gundersson LL, Tepper JE. Churchill Livingstone.
  4. Porter AT, Ben-Josef E, Mertens W, Ryan RJ. Prostate Cancer. In: Management of Metastatic Disease to the Musculoskeletal System. Ed: Heiner JP, Kinsella T, Zdeblick TA. Quality Medical Publishing Inc., St. Louis, MO. (in press).


Published Abstracts:

  1. Ben-Josef, E.; Einav, O.; Forman, J.D. Predicting the Outcome of Radiotherapy for Localized Prostate Cancer Using the Pattern of PSA Decline. Program/Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology. Vol. 12, March 1993.
  2. Forman, J.D.; Mesina, D.F.; He, T.; Devi, S.B.; Ben-Josef, E.; Pellizari, C.; Vijayakumar, S.; Chen, G.T. Evaluation of Changes in the Location and Shape of the Prostate and Rectum During A Seven Week Course of Conformal Radiotherapy. Proceedings of the American Society for Therapeutic Radiology and Oncology 35th Annual Meeting. Int. J. Radiation Oncology Biol. Phys., 27:222, 1993.
  3. Ben-Josef E, Shamsa F, Smith D, Forman JD. Early Prediction of Outcome of Radiotherapy for Localized Prostate Cancer Using the Pattern of PSA Decline. Proceedings of the Europian Society for Therapeutic Radiology and Oncology 13th Annual Meeting. Radiotherapy and Oncology 32 (Suppl. 1): S140, 1994.
  4. Lucas RD, Ben-Josef E, Vasan S, Porter AT. Selective accumulation of Strontium-89 in metastatic deposits in bone; radio-histological correlation. The U.S. and Canadian Academy of Pathology meeting. Toronto 1995.
  5. Ben-Josef E., Garde SV., Basrur V, Krishan A, Porter A.T. Prostate secretory protein of 94 amino-acids (PSP94) and a 10-mer synthetic analogue (R10) suppress growth and clonogenic cell survival in hormone-resistant prostate cancer. Program/Proceedings of the 31th Annual Meeting of the American Society of Clinical Oncology. Vol. 14 p 234, March 1995.
  6. Ben-Josef E., Mesina CF., Choi J, Forman JD. A nonaxial boost may reduce late complications of radiotherapy for prostate cancer Proceedings of the American Society for Therapeutic Radiology and Oncology 37th Annual Meeting. Int. J. Radiation Oncology Biol. Phys.32 (Suppl. 1):252, 1995.
  7. Ben-Josef E, Fontanesi J, Zalupski M, Brusseau TE, Ryan JR. Conservative resection without radiotherapy for local control of Ewing's sarcoma. Proceedings of the 8th European Cancer Conference, European Journal of Cancer 31A (Suppl): p S249-S250, 1995.
  8. Reddy SM, Ben-Josef E, Fontanesi J, Rayn JR, Zalupski M, Lucas D, Patel N, Gross M, Shamsa F, Porter AT. Extra-abdominal desmoid tumors. Role of high-dose rate brachytherapy and external beam radiation therapy as an adjuvant to surgical resection. 1st Scientific Meeting of the Connective Tissue Oncology Society, Boston, September 1995.
  9. Cuba PJ, Ben-Josef E, Zalupski M, Lucas D, Patell N, Gross M, Brusseau T, Shamsa F, Fontanesi J, Rayn JR, Porter AT. Brachytherapy in the treatment of soft-tissue sarcoma at Wayne State University. 1st Scientific Meeting of the Connective Tissue Oncology Society, Boston, September 1995.
  10. Patel N, Ben-Josef E, Lucas D, Zalupski M, Rayn JR. Case series report of chondrosarcoma treatment. 1st Scientific Meeting of the Connective Tissue Oncology Society, Boston, September 1995.
  11. Ryan JR, Chuba PJ, Ben-Josef E, Porter AT, Zalupski M, Lucas D, Patell N, Gross M, Brusseau TE, Filipczak L, Fontanesi J. Adjuvant brachytherapy for primary and recurrent soft-tissue sarcoma at WSU.. Int. 1st International Brachytherapy Meeting GEC/ESTRO-ABS-GLAC. Tours, France, May 13-15, 1996.
  12. E. Ben-Josef, A. Williams, W. Mertens, A.T. Porter. Survey of the radiotherapeutic management of bone metastases. Program/Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology. J Clinical Oncology Vol. 15 p 514, March 1996.
  13. Patel N, Ben-Josef E, Lucas D, Zalupski M, Rayn JR. Case series report of chondrosarcoma Michigan Orthopedic Society Annual Meeting. Mackinac Island, MI, June 13-15, 1996.
  14. Gallicchio VS, Hughes NK, Oakley O, Mayhew C, Piper J, Conaway DH, Platt D, Chang Y, Ben-Josef E. Increased survival with improved immune function in LP-BM5 MuLV induced murine immunodeficiency disease (MAIDS) with Multiple Mitogenic Stimulator (MMS1). Keystone Symposium on molecular and cellular biology: Immunopathogenesis of HIV infection. Hilton Head, South Carolina, March 26-April 1, 1996.
  15. Ben-Josef E, Shamsa F, Smith D, Forman JD. Prognostic factors in patients with clinically localized prostate cancer treated with 3D conformal radiotherapy. Proceedings of the 82nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, Radiology, 1996.
  16. Ben-Josef E, Vaishampayan N, Chuba P, Shamsa F, Fontanesi J, Ryan JR, Porter A.T. Local control of soft-tissue sarcoma with surgery and adjuvant radiotherapy: analysis of prognostic factors. Proceedings of the European Society for Therapeutic Radiology and Oncology 15th Annual Meeting. Radiotherapy and Oncology, 1996.
  17. Ben-Josef E, Filipzack L, Davis L, Porter AT. Repeated administration of strontium-89 for palliation of painful osseous metastases. Program/Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology. J Clinical Oncology Vol. 16 p 59a, March 1997.
  18. Garde SV., Basrur V, Li L, Finkelman M, Krishan A, Ben-Josef E., Haddad M, Taylor JD, Porter AT, Tang DG. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent human prostate cancer cells (PC3) in vitro and in vivo by inducing apoptosis.. Program/Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology. Vol. 16 p 546a, March 1997.
  19. Ben-Josef E, Chuba P, Fontanessi J, Ryan JR, Porter AT. Brachytherapy improves outcome of radiotherapy for soft-tissue sarcoma of the extremities. The European Cancer Conference 9, The European Journal of Cancer, Vol 33 (Suppl 8): p S111, 1997.
  20. Aref A, Ahmad E, Ben-Josef E, Fontanessi J, Jacobs J, Marks S, Arden R, Ensley J, Shamsa F. Complication rate following neutron or mixed beam irradiation for patients with head and neck malignancies. The European Cancer Conference 9, The European Journal of Cancer, Vol 33 (Suppl 8): p S189, 1997.
  21. Ben-Josef E, Chuba P, Fontanessi J, Zalupski M, Ryan JR, Filipzack L, Porter AT. Radiotherapy as a surgical adjunct in soft-tissue sarcoma of the retroperitoneum, pelvis, and trunk.. Proceedings of the American Society for Therapeutic Radiology and Oncology 35th Annual Meeting. Int. J. Radiation Oncology Biol. Phys., 39 (2S), p 355, 1997.
  22. Ben-Josef E, Shamsa F, Youssef E, Porter AT. External Beam Radiotherapy for Painful Osseous Metastases: Pooled Data Dose-Response Analysis. Radiology 209(P): p438, 1998.
  23. Ben-Josef E, Yap J, Chuba PJ, Fontanesi JN, Ahmad SB, Aref A. Neutron external beam radiotherapy for head and neck cancer. 81st Annual American Radium Society Meeting, Hapuna Beach Prince Hotel, Big Island of Hawaii. April 17-21, 1999.
  24. Ben-Josef E et al. Neoadjuvant estramustine/etoposide followed by concurrent estramustine and definitive radiotherapy for locally-advanced prostate cancer. 35th American Society of Clinical Oncology Annual Meeting, Atlanta World Congress Center, Atlanta Georgia. May 15-18, 1999.
  25. Forman JD, Tekyi-Mensah S, Bolton SE, Prokop S, Chuba PJ, Ben-Josef E, Porter AT, Maughan RL. Conformal sequential neutron-photon vs. photon-neutron irradiation in organ confined prostate cancer: results of a randomized prospective trial. Proceedings of the American Society for Therapeutic Radiology and Oncology 41st Annual Meeting, San Antonio, Texas. Int. J. Radiat. Oncol. Biol. Phys. 45(3S):168, Abstract #42, 1999.
  26. Yang S, Ziao Q, Kasza T, Yudelev M, Han S, Tang D, Ben-Josef E. Mitochondrial respiratory chain (MRC) function plays an important role in radition induced apoptosis. Proceedings of the American Society for Therapeutic Radiology and Oncology 41st Annual Meeting, San Antonio, Texas. Int. J. Radiat. Oncol. Biol. Phys. 45(3S):301, Abstract #2047, 1999.
  27. Forman JD, Tekyi-Mensah S, Bolton SE, Chuba PJ, Ben-Josef E, Porter AT, Maughan RL. American Urological Association 95th Annual Meeting, Atlanta, Georgia, April 29-May 4, 2000. Results of a randomized prospective trial of sequential neutron-photon versus photon-neutron irradiation in organ confined prostate cancer.
  28. Balani J, Shields A, Vaitkevicius V, Ben-Josef E, Levin K, Sarkar F, Cheng J, Adsay V. Pathological findings in post-neoadjuvant pancreatectomy specimensUnited States and canadian Academy of Pathology.
  29. E Ben-Josef, A Porter, S Han, B Vargas, J Fontana, M Hussain. Chemoradiotherapy for localized high-risk prostate cancer. Proceedings of the European Society for Therapeutic Radiology and Oncology 19th Annual Meeting. Radiotherapy and Oncology 56 (supplement 1): S66, 2000.
  30. E. Ben-Josef, U.N. Vaishampayan, V. Vaitkevicius, K. Levin, P. Philip, A. Shields. ASCO (2001). A single institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
  31. WA Sakr, S Upadyay, A Porter, DG Tang, TH Ji, P Tabaczka, E Ben-Josef. ASCO (2001). Over expression of the receptor for Follicle-Stimulating Hormone (FSHR) in adenocarcinoma of the prostate is associated with higher rates of relapse following radical prostatectomy.
  32. WA Sakr, S Upadyay, A Porter, DG Tang, TH Ji, P Tabaczka, E Ben-Josef. AUA (2001). Immunohistochemical expression of Follicle-Stimulating Hormone Receptor in human prostate cancer and high-grade PIN. EF Youssef, J Fontanesi, M Mott, M Kraut, D Lucas, M Gross, H Mikhael, E Ben-Josef. ASCO (2001).Prognostic factors in retroperitoneal and deep trunk soft-tissue sarcoma.
  33. E Ben-Josef, B Vargas, S Han, M Tobi, I Kaplan. (Submitted to ASTRO). Intrarectal application of amifostine for prevention of late radiation rectal injury: preliminary results of a phase I dose-escalation study.


Presentations:


International and National

  1. Predicting the Outcome of Radiotherapy for Localized Prostate Cancer Using the Pattern of PSA Decline. 1993 Meeting of the American Society of Clinical Oncology. Orlando, Florida, May 1993.
  2. Early Prediction of Outcome of Radiotherapy for Localized Prostate Cancer Using the Pattern of PSA Decline. 13th annual meeting of the European Society for Therapeutic Radiology and Oncology. Granada, Spain, September 1994.
  3. Whole Abdominal Radiotherapy and Concomitant 5-Fluorouracil as Adjuvant Therapy in Advanced Colon Cancer. International Symposium: Oncology ' 94. State of the art; update; prospects for the future. Herzlia, Israel, October 1994.
  4. Conservative resection without radiotherapy for local control of Ewing's sarcoma. The 8th European Cancer Conference. Paris, France, November 2, 1995.
  5. The role of hormonal cytoreduction in locally advanced prostate cancer. The 4th International Symposium on GnRh Analogues in Cancer and Human Reproduction. Geneva, Switzerland, February 8-11, 1996.
  6. Neutron radiotherapy for salivary gland tumors at Harper Hospital. Current status and future directions in particle therapy. An international particle therapy meeting in conjunction with PTCOG XXIV, Detroit, MI, April 26, 1996.
  7. Prognostic factors in patients with clinically localized prostate cancer treated with 3D conformal radiotherapy. Ben-Josef E, Shamsa F, Smith D, Forman JD. 82nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, December 1-6, 1996.
  8. The management and prevention of radiotherapy complications in H&N cancer, Advances in the management of Head and Neck cancer. Winnipeg, Canada, March 1997.
  9. Radiation therapy for locally advanced prostate cancer. Transperineal brachytherapy for early stage prostate cancer: The state of the art. Seattle, WA, June 13-14, 1997.
  10. External Beam Radiotherapy for Painful Osseous Metastases: Pooled Data Dose-Response Analysis. 84th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, Illinois, December 3, 1998.
  11. Neoadjuvant estramustine/etoposide followed by concurrent estramustine and definitive radiotherapy for locally-advanced prostate cancer. Fourth Annual National Veteran's Administration Oncology Symposium, Washington, D.C., October 8, 1999.
  12. Understanding Growth Regulation in Hormone-Refractory Prostate Cancer: Opportunities for New Therapeutic Interventions. In: Prostate Cancer; Multihormonal Influences. A CME Mini-symposium. American College of Radiation Oncology, Washington, D.C., May 6, 2000.
  13. Follicular Stimulating Hormone in Prostate cancer. In: Amgen Praecis Roundtable on Prostate Cancer: A Multi-Hormonal Perspective. Washington, D.C., May 7, 2000.
  14. The potential role of FSH and its recepor in prostate cancer. The Annual Convention and Scientific Assembly of the National Medical Association. Washington DC, August 15, 2000
  15. The potential role of FSH and its recepor in prostate cancer. The 1st meeting of the International Task Force on FSH in Prostate Cancer. Puerto Rico, December 8-10, 2000.
  16. Introduction to clinical radiobiology; principles of radioprotection and radiosensitization. Roche Laboratories. October 25, 2000
  17. Chemoradiotherapy, radiosensitization and radioprotection in the treatment of localized prostate cancer. SWOG Fall Group Meeting, New Orleans, LO, October 12, 2000.

Local and regional

  1. Salvage Cystectomy After Radical Treatment for Urinary Bladder Cancer. Updates in the Treatment of Bladder Cancer. Belinson Medical Center, Israel, November 1989.
  2. Transferrin-Gadolinium Complexes as a Cancer Specific MR-Contrast Agent. Radiation Oncology Research Day. Wayne State University, Detroit, MI, 1992
  3. Adjuvant Whole Abdomen Irradiation with Concomitant 5-FU for Locally Advanced Colon Cancer above the Peritoneal Reflection. 1993 Annual Meeting of the Michigan Society for Radiation Therapy, Novi, Michigan, April 1993.
  4. Strontium-89 in the Treatment of painful osseous metastases. New developments in prostate cancer management. Pebble Beach, California, January 1995.
  5. Endocrine resistant prostate cancer. 17th annual meeting of the Ohio Valley-Lake Erie Association of Cancer Centers. Oregon, Ohio, October 14, 1995.
  6. Neutron radiotherapy for Head & Neck cancer. Tel-Aviv University Sackler School of Medicine, Oncology CME program, Tel-Aviv, Israel, March 29, 1996.
  7. Strontium-89 and other systemic radioisotopes for the treatment of painful osseous metastases. Joint Meeting of the American Association for Clinical Chemistry and Clinical Ligand Assay Society, Canton, Michigan, June 4, 1998.
  8. Treatment of bone metastases from prostate cancer. 22nd Annual Meeting of the Midwest Clinical Ligand Assay Society, Romulus, Michigan, October 23, 1998.
  9. New approaches to the treatment of locally advanced prostate cancer. Arlington Cancer Center, Irving, Texas, October 27, 1999.
  10. The potential role of FSH and its recepor in prostate cancer. Department of Urology, Duke University, Durham, NC, November 29, 2000.
  11. Gastrointestinal Oncology Update. Sponsored by Wayne State University School of Medicine, Division of Continuing Medical Education. Course co-organizer. Dearborn, MI, October 28, 2000.
  12. Radiosensitization with 5-FU and Capecitabine (Xeloda). Rush-Copley-Mercy CME Consortium, Aurora, IL, March 16, 2001.